CRDMO

WuXi AppTec (603259.SH/2359.HK) announced its first interim dividend, distributing RMB 1.03 billion to shareholders, demonstrating financial strength and commitment to shareholder value. Year-to-date, the company has distributed RMB 4.88 billion in dividends and repurchased shares, totaling RMB 6.88 billion in shareholder returns – over 70% of its 2024 net profit. This reflects confidence in future growth and strong cash flow. WuXi AppTec’s CRDMO platform is driven by increasing demand for R&D and manufacturing services, positioning it as a key partner for global pharmaceutical and biotech companies.

WuXi Biologics (2269.HK) announced SBTi approval of its near-term and net-zero GHG emissions reduction targets, aligning with 1.5°C pathways and committing to net-zero across its value chain by 2050. As a leading Green CRDMO, WuXi Biologics implements a comprehensive strategy, engaging suppliers to reduce its environmental footprint. CEO Dr. Chris Chen views this as a catalyst for further action and delivering ESG excellence. The company holds MSCI AAA Rating, EcoVadis Platinum Medal, and DJSI listing.